Congruence Therapeutics: finding a fix for misfolded proteins

Congruence Therapeutics: finding a fix for misfolded proteins


Stabilizing the unstable may be the road to therapeutics for unmet needs.

  1. Michael Eisenstein

    1. Philadelphia, Pennsylvania, USA

All the instructions for proper folding are directly encoded in a protein’s amino acid sequence. This means that even subtle mutations affecting a single residue can derail the folding process, distorting that protein’s structure and thereby impeding or even fully disabling its function. Clarissa Desjardins, a serial biotech entrepreneur with a longstanding interest in developing therapies for rare diseases, recognized this vulnerability as an opportunity. “A lot of the rare diseases that I was looking at were partial loss of function due to misfolded proteins,” she says. “And I learned that these misfolded proteins can be stabilized by small molecules.” In 2021, Desjardins founded Congruence Therapeutics in Montreal with the goal of discovering and developing ‘pharmacological chaperone’ drugs that can effectively restore normal folding to mutated proteins.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


Read More

Leave a Reply

Your email address will not be published. Required fields are marked *